The authors reported that at diagnosis, survivin levels in patients with ALL were higher than in the control group (range: 28.0 ± 11.2 vs. 3.3–14.8 pg/mL; p = 0.00), showing a considerable reduction in survivin levels after therapy. Here, BIRC5 is linked to acute lymphoblastic leukemia.